ClinicalTrials.gg
Not yet recruitingNCT06902922Tri-GuMUpdated Mar 30, 2025

Impact of Severe Tricuspid Regurgitation Correction on Gut Microbiota and Gastrointestinal Function

An observational study in Tricuspid Regurgitation (TR), sponsored by Francesco Maisano. Not yet recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-30.

Sponsored by Francesco Maisano · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Tricuspid Valve Insufficiency with a site in Italy — 16 open to participants now, 19 under way, none of them phase 3. Tricuspid Valve Insufficiency · Italy.

Planned enrollment
17th of 23
150 · median 250
Started
2025
with 3 others
Observational
23 of 32
14 open now
Primary completion
2027-03
later than 12 of 18 live
Registered
30th of 32
by date

Among the 32 studies in Tricuspid Valve Insufficiency with a site in Italy, this one is the 17th largest by planned enrollment of the 23 observational ones that give a count, is one of 4 that started in 2025, is one of 23 observational ones, reaches primary completion later than 12 of the 18 other live ones, and was the 30th registered.

Tricuspid Valve Insufficiency

229 studies on the registry are indexed under Tricuspid Valve Insufficiency; 111 are open to participants now.

Browse Tricuspid Valve Insufficiency studies →

Open to participants now

16 of the 32 studies in Tricuspid Valve Insufficiency with a site in Italy are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 81 Tricuspid Valve Insufficiency studies recruiting now, 67 (83%) set no upper age limit and none (0%) stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Tricuspid Valve Insufficiency with a site in Italy, or all of them as a file.
02

Study summary

Tricuspid regurgitation (TR) is gaining increasing attention within the cardiological community due to its poor prognosis, challenging clinical presentation and difficult treatment.

TR causes decreased forward cardiac output and increased intravascular pressure upstream, which lead to peripheral oedema, ascites, hepatic congestion and kidney failure.

The microbiota is also getting increasing attention and changes in microbiota have been already associated with cardiovascular disease.

The impact of hemodynamic effects of TR on the gut microbiota however is still unknown.

Patients affected by TR frequently complain abdominal distension and anorexia. We hypothesize that, due to increased venous congestion, TR may induce impaired gut function with modification in the microbiota and that TR correction may induce reverse changes.

This study will enroll patients treated with Transcatheter Tricuspid Edge-to-Edge Repair (T-TEER) at the Valve Center of San Raffaele Hospital due to severe TR.

In addition to the standard of care, before T-TEER, for all patients 2 additional blood samples, 1 urine and 1 fecal sample will be collected.

3 months after the procedure, all patients will be re-assessed at the Valve Center outpatient clinic as standard of care. At this stage for all patients 2 blood samples, 1 urine and 1 fecal sample will be collected again for the purpose of the study. The microbiota metabolites of patients after 3 months from the procedure will be compared to those at baseline according to the degrees of residual TR.

To assess the reproducibility of the microbiota results and to explore an intrinsic short-term variation in microbiome composition within single patients, a subgroup of 30 patients will undergo a low intervention substudy repeating the measurements (2 blood, 1 urine and 1 fecal) within 10 days, both at baseline and at follow-up.

03

Conditions studied

  • Tricuspid Regurgitation (TR)

Keywords

  • tricuspid regurgitation
  • gut microbiota
  • gastrointestinal
  • heart
  • heart valve disease
  • tricuspid valve disease
  • transcatheter
  • T-TEER
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with TR ≥ severe who will undergo T-TEER

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, able to sign the Form, admitted to OSR Heart Valve Center with TR ≥ severe treated with T-TEER.

Exclusion criteria

Exclusion Criteria:

  • Concomitant ≥ severe MR. Such patients may be treated with M-TEER and be re-evaluated after 3 months: if TR is ≥ severe and MR is ≤ moderate the patient may then be enrolled.
  • Surgical candidates
  • Recent \< 6 months cardiac coronary or structural procedure
  • CAD requiring intervention
  • other valvular disease > moderate
  • Treatment with transcatheter tricuspid replacement
  • Age \<18 years
  • Inability or unwillingness to sign
  • Kidney dialysis
  • Acute infection
  • Inflammatory bowel diseases
  • Gastrointestinal diseases
  • Previous gastrointestinal surgery
  • Active cancer
  • Active or inflammatory diseases
  • Treatments with antibiotics or probiotics within one month
  • Emergency procedures
  • Patients enrolled in interventional studies that may confound study results
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • T-TEER

    Adult patients, able to sign the Informed Consent Form, with TR ≥ severe who will be treated with T-TEER

06

What researchers measure

Primary outcomes

  1. Gut Microbiota Changes

    The microbiota metabolites production in patients affected by severe TR and their changes after transcatheter TR correction will be measured at 3-months, compared to baseline, in terms of c differential abundance in microbiota metabolites, according to residual TR groups

    Time frame: 3 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2025; primary completion for Mar 2027, 24 months later.

Of 47 observational studies under Tricuspid Valve Insufficiency, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 106. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2025
First posted
Mar 30, 2025
StartEst.
Mar 31, 2025
Primary completionEst.
Mar 31, 2027
CompletionEst.
Sep 30, 2027
Last update
Mar 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06902922
Lead sponsor
Francesco Maisano
Collaborators
IRCCS Ospedale San Raffaele, Abbott
Responsible party
Francesco Maisano (Head of Cardiac Surgery Department; Director of the Heart Valve Center, IRCCS Ospedale San Raffaele) — Sponsor-investigator
First posted
Mar 30, 2025
Start date
Mar 31, 2025 (estimated)
Primary completion
Mar 31, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Mar 30, 2025

Study contacts

Clinical Trial Coordinator
Contact
schiavi.davide@hsr.it
+39 0226435316

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion